Duquesne Light

Nuclear Group
P.O. Box 4
Shippingport, PA 15077-0004

Telephone (412) 393-6000

December 18, 1990
NG3VPN:6460

United States Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, DC 20555

Reference: Beaver Valley Power Station
BV-1 Docket No. 50-334, License No. DPR-66
BV-2 Docket No. 50-412, License No. NPF-73

Gentlemen:

Following is a report under 10CFR26, Appendix A, paragraph 2.8(e)(5), of the Fitness for Duty Rule:

Specifically, the above referenced guidelines require that the licensee promptly notify the NRC should a false positive error occur on a blind performance test specimen and the error is determined to be an administrative error.

As a result of an inquiry performed by our Fitness-For-Duty Program staff, we have determined that between October 23, 1990 and November 27, 1990, nineteen blind performance samples were incorrectly analyzed by Roche Biomedical Laboratory in Dublin, Ohio. Seven of the samples analyzed incorrectly were spiked at exactly the cutoff level of 100 ng/ml and metabolite dissipation might have been expected to yield a negative test result. All other samples were spiked at 140% or more of the cutoff level.

These blind performance test samples were obtained from Southgate Medical Laboratory System, Cleveland, Ohio and certified positive by the toxicologist for the substance claimed.

We were notified on December 7, 1990 that Roche Laboratory in Dublin, Ohio, was partially suspended from conducting confirmation testing for amphetamines until further notice and that confirmation testing for amphetamines will be referred to another NIDA certified Roche Laboratory.

A021
1/1

As a result, we have requested a retest by an independent laboratory of the nineteen samples originally reported as negative from Roche Laboratory. We continue to use quality control blind samples from Southgate Laboratory but we are in process of obtaining FDA approved blind samples for performance testing at Roche Laboratories. Roche Laboratories has committed to continue their cooperation with NIDA to determine why this testing discrepancy occurred. We are continuing our efforts with Roche Laboratories to ensure that acceptable performance standards are maintained.

If you have any questions concerning this matter, please contact my office.

Very truly yours,

J. D. Sieber

J. D. Sieber
Vice President
Nuclear Group

Enclosures:

Attachment I, Southgate's November 21, 1990 letter.
Attachment II, Roche's December 6, 1990 letter.
Attachment III, Request for Retest, November 30, 1990 letter.

cc: Mr. J. Beall, Sr. Resident Inspector
Mr. T. T. Martin, NRC Region I Administrator
Mr. L. L. Bush, NRC Reactor Safeguards Branch
Mr. A. W. DeAgazio, NRC Project Manager

ATTACHMENT I

SOUTHGATE
MEDICAL LABORATORY SYSTEM
OWNED AND OPERATED BY SOUTHGATE MEDICAL SERVICES, INC.

LABORATORY DIRECTOR
EDWARD E. SIEGLER, M.D.

CHIEF EXECUTIVE OFFICER
CHARLES J. SILVERMAN, J.D.

21100 SOUTHGATE PARK BOULEVARD
CLEVELAND, OHIO 44137-3054
(216) 581-1030
1-800-362-8813 (OHIO) • 1-800-338-0188 (OUTSIDE OHIO)

BILLING INQUIRIES
MAR DATA SYSTEMS
(216) 581-1714
1-800-833-8455 (OHIO)

November 21, 1990

Darlene Kopp, R.N.
Duquesne Light
Beaver Valley Power Station
Route 168
Shippingport, PA 15077

Dear Ms. Kopp,

Pursuant to your request, I have retrieved the quantitative results for the proficiency samples listed below, and have enclosed copies of the GC/MS quantitative reports. All of these samples are made up in pooled urine collected from the Toxicology staff, which is screened by EMIT and GC/MS to assure that the pool is negative. We then spike the individual pools using pure drugs or drug metabolites to levels that are normally 40% or more above the screening cutoffs specified in the DHHS Regulations. Additionally, you had also requested a Cannabinoid Pool that was at 100 ng/ml. I have listed below, what form of the drug or drug metabolite that we use, and the source from which we obtain these standards. All of these standards are check for purity prior to use.

Analyte/Form	Source
Amphetamine HCL	Alltech Applied Science
Methamphetamine HCL	Alltech Applied Science
Benzoylecgonine Tetrahydrate	Alltech Applied Science
11-nor-delta-9-THC-COOH (THC-COOH)	Research Triangle Institute

Certified Positive Urine Pool: Amphetamine, Methamphetamine lot 060190

Amphetamine	1450 ng/ml	45.0% above cutoff
Methamphetamine	1415 ng/ml	41.5% above cutoff

ATTACHMENT I

Certified Positive Urine Pool: Amphetamine, Methamphetamine, Cannabinoids lot 060190

Amphetamine	1414 ng/ml	41.4% above cutoff
Methamphetamine	1497 ng/ml	49.7% above cutoff
THC COOH	203.4 ng/ml	103 % above cutoff

Certified Positive Urine Pool: Benzoylecgonine, Cannabinoids lot 060190

Benzoylecgonine	995.1 ng/ml	231 % above cutoff
THC-COOH	200.1 ng/ml	100 % above cutoff

Certified Positive Urine Pool: Cannabinoids 100 ng/ml lot 101890

THC-COOH	106.6 ng/ml 103.5 ng/ml	
mean	105.1 ng/ml	5.1 % above cutoff

Should you require any additional information, or if I can be of further service, please call me at 1-800-338-0166 extension 256.

Sincerely,

Neil A. Fortner, M.S.
Scientific Director - Toxicology

ATTACHMENT I

*** Internal Standard ***

Operator: DP 06/19/90 19 Jun 90 8:14 pm
Method File Name : AMINES.M
Sample Info : CERTIFIED POSITIVE LOT 060190 # 05968
Misc Info: MSD 3
Integration File Name : DATA:061SC19A.I
Method Index : 2 Bottle Number : 19

Last Update: 20 Jun 90 8:41 am
Reference Peak Window: 5.00 % of Retention Time
Non-Reference Peak Window: 5.00 % of Retention Time
Sample Amount: 0.000 Uncalibrated Peak RF: 0.000 Multiplier: 1.000

Peak Num	Type	Int Type	Ret Time	Signal Description	Compound Name	Area	Amount
1	ISTD	1BV	8.228	Mass 96.00 amu	AMPHET DS	6372228	200.0 NG/ML
2		1BV	9.031	Mass 91.00 amu	METHAMPHET	18526068	1415 NG/ML

*** Internal Standard ***

Operator: DP 06/19/90 19 Jun 90 8:14 pm
Method File Name : AMINES.M
Sample Info : CERTIFIED POSITIVE LOT 060190 # 05968
Misc Info: MSD 3
Integration File Name : DATA:061SC19A.I
Method Index : 2 Bottle Number : 19

AMPHETAMINE IN URINE

Last Update: 20 Jun 90 8:22 am
Reference Peak Window: 5.00 % of Retention Time
Non-Reference Peak Window: 5.00 % of Retention Time
Sample Amount: 0.000 Uncalibrated Peak RF: 0.000 Multiplier: 1.000

Peak Num	Type	Int Type	Ret Time	Signal Description	Compound Name	Area	Amount
1	ISTD	1BV	8.228	Mass 96.00 amu	AMPHET DS	6372228	200.0 NG/ML
2		1BV	8.258	Mass 91.00 amu	AMPHETAMINE	19247277	1450 NG/ML

ATTACHMENT I

Operator: MK-GC 06/20/90 20 Jun 90 5:21 pm
Method File Name : THC.M
Sample Info : THC CERTIFIED POSITIVE LOT 060190 # 05967
Misc Info: MSD 1
Integration File Name : DATA:0620C06A.I
Method Index : 1 Bottle Number : 6

THC-COOH IN URINE

Last Update: 2[illegible] Jun 90 7:51 am
Reference Peak Window: 5.00 % of Retention Time
Non-Reference Peak Window: 5.00 % of Retention Time
Sample Amount: 0.000 Uncalibrated Peak RF: 0.900 Multiplier: 1.000

Peak Num	Type	Int Type	Ret Time	Signal Description	Compound Name	Area	Amount
1	ISTD	IBB	9.629	Mass 374.00 amu	THC-COOH D3	6332803	100.0 NG/ML
2		IBBA	9.659	Mass 371.00 amu	THC-COOH	34357014	203.4 NG/ML

*** Internal Standard ***

Operator: DP 06/19/90 19 Jun 90 8:41 pm
Method File Name : AMINES.M
Sample Info : CERTIFIED POSITIVE LOT 060190 # 05967
Misc Info: MSD 3
Integration File Name : DATA:0619C21A.I
Method Index : 2 Bottle Number : 21

Last Update: 20 Jun 90 8:41 am
Reference Peak Window: 5.00 % of Retention Time
Non-Reference Peak Window: 5.00 % of Retention Time
Sample Amount: 0.000 Uncalibrated Peak RF: 0.000 Multiplier: 1.000

Peak Num	Type	Int Type	Ret Time	Signal Description	Compound Name	Area	Amount
1	ISTD	IBV	8.229	Mass 96.00 amu	AMPHET D5	7113556	200.0 NG/ML
2		IBV	8.032	Mass 91.00 amu	METHAMPHET	21520818	1497 NG/ML

*** Internal Standard ***

Operator: DP 06/19/90 19 Jun 90 8:41 pm
Method File Name : AMINES.M
Sample Info : CERTIFIED POSITIVE LOT 060190 # 05967
Misc Info: MSD 3
Integration File Name : DATA:0619C21A.I
Method Index : 2 Bottle Number : 21

AMPHETAMINE IN URINE

Last Update: 20 Jun 90 8:22 am
Reference Peak Window: 5.00 % of Retention Time
Non-Reference Peak Window: 5.00 % of Retention Time
Sample Amount: 0.000 Uncalibrated Peak RF: 0.000 Multiplier: 1.000

Peak Num	Type	Int Type	Ret Time	Signal Description	Compound Name	Area	Amount
1	ISTD	IBV	8.229	Mass 96.00	AMPHET D5		

ATTACHMENT I

*** Internal Standard ***

19 Jun 90 7:11 pm

Operator: HR/GC 061990
Method File Name : BE.M
Sample Info : BE CERTIFIED POSITIVE LOT #060190, #05964
Misc Info: MSD 1
Integration File Name : DATA:0619B05A.I
Method Index : 2 Bottle Number : 5

BENZOYLECGONINE IN URINE

Last Update: 20 Jun 90 7:58 am
Reference Peak Window: 5.00 % of Retention Time
Non-Reference Peak Window: 5.00 % of Retention Time
Sample Amount: 0.000 Uncalibrated Peak RF: 0.000 Multiplier: 1.000

Peak Num	Type	Int Type	Ret Time	Signal Description	Compound Name	Area	Amount
1	+ISTD	BV	8.684	Mass 243.00 amu	BE D3	8739144	200.0 NG/ML
2		BV	8.698	Mass 240.00 amu	BE	24463681	985.1 NG/ML

*** Internal Standard ***

20 Jun 90 5:47 pm

Operator: HR/GC 06/20/90
Method File Name : THC.M
Sample Info : THC CERTIFIED POSITIVE LOT 060190 # 05964
Misc Info: MSD 1
Integration File Name : DATA:0620A10A.I
Method Index : 1 Bottle Number : 10

THC-COOH IN URINE

Last Update: 21 Jun 90 7:51 am
Reference Peak Window: 5.00 % of Retention Time
Non-Reference Peak Window: 5.00 % of Retention Time
Sample Amount: 0.000 Uncalibrated Peak RF: 0.000 Multiplier: 1.000

Peak Num	Type	Int Type	Ret Time	Signal Description	Compound Name	Area	Amount
1	ISTD	BB	9.622	Mass 374.00 amu	THC-COOH D3	4868933	100.0 NG/ML
2		BV	9.648	Mass 371.00 amu	THC-COOH	13089020	200.1 NG/ML

ATTACHMENT I

*** Internal Standard ***

Operator: HR 11/05/90 6 Nov 90 1:50 pm
Method File Name : THC.M
Sample Info : 100 NG/ML THC-COOH POOL
Misc Info: MSD 2
Integration File Name : DATA:1105A09A.I
Method Index : 1 Bottle Number : 9

Last Update: 6 Nov 90 7:51 pm
Reference Peak Window: 5.00 % of Retention Time
Non-Reference Peak Window: 5.00 % of Retention Time
Sample Amount: 0.000 Uncalibrated Peak RF: 0.000 Multiplier: 1.000

Peak Num	Type	Int Type	Ret Time	Signal Description	Compound Name	Area	Amount
1	ISTD	IBV	9.133	Mass 374.00 amu	THC-COOH D3	11150728	100.0 NG/ML
2		IBV	9.159	Mass 371.00 amu	THC-COOH	12742112	105.5 NG/ML

*** Internal Standard ***

Operator: HR 11/05/90 6 Nov 90 2:03 pm
Method File Name : THC.M
Sample Info : 100 NG/ML THC-COOH POOL
Misc Info: MSD 2
Integration File Name : DATA:1105A10A.I
Method Index : 1 Bottle Number : 10

Last Update: 6 Nov 90 7:51 pm
Reference Peak Window: 5.00 % of Retention Time
Non-Reference Peak Window: 5.00 % of Retention Time
Sample Amount: 0.000 Uncalibrated Peak RF: 0.000 Multiplier: 1.000

Peak Num	Type	Int Type	Ret Time	Signal Description	Compound Name	Area	Amount
1	ISTD	IBV	9.134	Mass 374.00 amu	THC-COOH D3	10847473	100.0 NG/ML
2		IBV	9.159	Mass 371.00 amu	THC-COOH	12023202	103.5 NG/ML

ATTACHMENT II

Roche Biomedical Laboratories
a subsidiary of Hoffmann-La Roche Inc

Roche Biomedical Laboratories, Inc
6364 Dublin Industrial Lane
Dublin, Ohio 43017

Telephone (614) 889-2761

December 6, 1990

Dear Client:

Roche Biomedical Laboratories (RBL) received notification from the National Institute on Drug Abuse (NIDA) that our Dublin, Ohio facility has been partially suspended from conducting confirmation testing for amphetamines, one of the drugs tested under the NIDA program. The Dublin, Ohio facility remains certified by NIDA to conduct screening for amphetamines as well as screening and confirmation for the other drugs tested under the NIDA program. Until the suspension is lifted, we will refer all presumptive positive amphetamines to one of Roche Biomedical's other NIDA certified laboratories for confirmation.

As our client, however, you can expect your service to continue uninterrupted and unaffected. RBL remains committed to providing quality laboratory services.

Roche has substituted the method in question with an alternative procedure for amphetamine confirmation. Since the new procedure is now in place, Roche Biomedical anticipates that NIDA will lift the partial suspension soon. Moreover, we will continue our cooperation with NIDA to determine why this testing discrepancy occurred.

If you have any questions or concerns, please contact Dr. Donald Long, Director of Toxicology or Steve Jones, General Manager for our Dublin, Ohio facility, or me. We can be reached at (800) 282-7300.

Sincerely,

James R Mott

James R. Mott
Senior Vice President
Central Region

JRM/pd

Duquesne Light

Nuclear Group
P.O. Box 4
Shippingport, PA 15077-0004

Telephone (412) 393-6000

November 30, 1990
NMS: 0034

Donald W. Long, Ph.D.
Roche Labs
P.O. Box 2289
Columbus, OH 43216

Dear Dr. Long:

The following 19 proficiency samples were sent to Roche Biomedical Laboratory from October 23, 1990 through November 27, 1990:

303-714-0306-0	B-9756314-D	10-29-90
303-714-0319-0	B-9756323-D	10-29-90
298-714-0426-0	B-9886793-D	10-24-90
299-714-0253-0	B-9886760-D	10-25-90
305-714-0337-0	B-9756336-D	11-01-90
306-714-0287-0	B-9756380-D	11-02-90
305-714-0347-0	B-9756347-D	10-31-90
306-714-0215-0	B-9756386-D	11-02-90
296-714-0486-0	B-9886318-D	10-23-90
296-714-0487-0	B-9886316-D	10-23-90
298-714-0318-4	B-9886795-D	10-24-90
299-714-0305-4	B-9886764-D	10-25-90
299-714-0357-4	B-9886756-D	10-25-90
303-714-0324-0	B-9886754-D	10-29-90
309-714-0430-0	B-9756355-D	11-01-90
306-714-0277-0	B-9756352-D	11-01-90
305-714-0336-0	B-9756335-D	10-31-90
332-714-0277-0	B-9756499-D	11-27-90
324-714-0360-0	B-9756494-D	11-19-90

Upon receipt of the results, several discrepancies were noted, primarily in the cannabinoid and methamphetamine spiked samples.

We are requesting a retest of the samples, including GC/MS, by and independent NIDA certified laboratory, at the expense of Duquesne Light Company. The listed samples are to be sent to:

Clinical Pathology Facility, Inc.
711 Bingham Street
Pittsburgh, PA 15203

ATTN: Fred Fochtman, Ph.D. (DABFT)
or James E. McLean, Director of Marketing Services

Dr. Fochtman stipulated that Roche Labs may provide the above samples with a Roche chain of custody form or contact Clinical Pathology Facility, Inc. (412-488-7500) to provide their chain of custody forms. If there is any further information required, please contact me at 412-393-7847.

Sincerely,

Gregg S Zernich DO

Gregory S. Zernich, D.O.
Medical Review Officer
Beaver Valley Power Station

GSZ/mab

bc: Fred Fochtman, Ph.D. - Clinical Pathology Facility, Inc.
Patricia A. Casasanta - Duquesne Light Company